Treating hepatitis C
Open Access
- 29 November 2005
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 42 (6) , 1455-1458
- https://doi.org/10.1002/hep.20975
Abstract
Viruses depend on host-derived factors for their efficient genome replication. Here, we demonstrate that a cellular peptidyl-prolyl cis-trans isomerase (PPIase), cyclophilin B (CyPB), is critical for the efficient replication of the hepatitis C virus genome. CyPB interacted with the HCV RNA polymerase NS5B to directly stimulate its RNA binding activity. Both the RNA interference (RNAi)-mediated reduction of endogenous CyPB expression and the induced loss of NS5B binding to CyPB decreased the levels of HCV replication. Thus, CyPB functions as a stimulatory regulator of NS5B in HCV replication machinery. This regulation mechanism for viral replication identifies CyPB as a target for antiviral therapeutic strategies.Keywords
This publication has 28 references indexed in Scilit:
- Suppression of Hepatitis C Virus Replication by Cyclosporin A Is Mediated by Blockade of CyclophilinsGastroenterology, 2005
- Hepatitis C and liver transplantationNature, 2005
- Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature, 2005
- Cyclophilin B Escorts the Hepatitis C Virus RNA Polymerase: A Viral Achilles Heel?Molecular Cell, 2005
- Progress toward the therapy of hepatitis with RNAi† ‡Hepatology, 2005
- Noise amidst the silence: off-target effects of siRNAs?Trends in Genetics, 2004
- The Role of Ribavirin–Induced Mutagenesis in Hcv Therapy: A Concept or A Fact?Hepatology, 2003
- Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trialsHepatology, 1997
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986
- TREATMENT OF CHRONIC HEPATITIS DUE TO HEPATITIS B VIRUSThe Lancet, 1985